1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
612084D601F6F0ACB002585700018CDFE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/evolving-patient-advocacy-relationships-support-programs-during-covid-19-pandemic
18
19
2018.97.14.81
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Patient Focused Services » Patient Advocacy Groups

Patient Support Excellence: Critical Programs, Tactics & Tools to Ensure Strong Advocacy & Access to Medicine during COVID-19 and Beyond

ID: CM-6


Features:

6 Info Graphics

15 Data Graphics

260+ Metrics

7 Narratives


Pages: 30


Published: 2020


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
In wake of the COVID-19 pandemic outbreak, many organizations have poured greater resources and attention into patient advocacy and support programs to ensure continued access to medicines and treatments.


Best Practices, LLC conducted this benchmarking research to understand critical patient advocacy and support trends which have arisen in response to COVID-19 - and which will drive patient support excellence in the future.

This report examines key support programs, tools, digital channels, communication frequency, performance measurement, staffing and other vital topics.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Health Care; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Agios; Alnylam Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; CSL Behring; Daiichi Sankyo; Genmab; Ironwood; Merck KGaA; Milestone Pharmaceuticals; MSD; Nestle Health Science; Novartis; OTSUKA; Pfizer; Retrophin; Sanofi; Takeda Pharmaceuticals; Theravance

Study Snapshot

Best Practices, LLC engaged 24 leaders at 20 biopharma companies in this research through a benchmarking survey. Nearly 60% of the participants serve at the Director / Head level or above.

Key topics covered in this report include:

  • Creative solutions for continuity of patient care
  • Implications of digital technology implementation
  • Evolvement and impact of patient assistance/support programs
  • Usage and effectiveness of performance metrics
  • Key patient support tools
  • Communication frequency and staffing
  • Post-pandemic changes to supporting advocacy groups

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Key patient support tools: Online FAQs provide answers to the most critical questions. Over 40% of companies who do not utilize this tool plan to do so in the next six weeks.
  • Advocacy group virtual engagement: Virtual platforms allow accessibility to online resources via support group sites and digital surveys for patients. There is a learning curve to using new technology platforms which may hamper present cross-collaboration.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Overviewpgs. 3-5
Universe of Learningpg. 4
Key Actionspg. 5
II.
Creative Solutions and Operational Implications of Technology Usepgs. 6-8
III.
Impact of Patient Support Programs and Metrics Usedpgs. 9-16
IV.
Communication Frequency, Staffing, and Post-Pandemic Changepgs. 17-22
V.
Participant Demographicspgs. 23-25
VI.
Appendixpgs. 26-29
VII.
About Best Practices, LLCpg. 30

    List of Charts & Exhibits

    I. Creative Solutions and Operational Implications of Technology Use

    • Creative solutions implemented around continuity of patient care during COVID-19
    • Successes and challenges faced by benchmark participants in implementing digital technology and platforms to reach and engage with patients through patient advocacy groups

    II. Impact of Patient Support Programs and Metrics Used

    • Evolvement of patient assistance / support programs during COVID-19 crisis
    • Impact of COVID-19 crisis on patient support / assistance programs
    • Virtual engagement with patients
    • Case study: Manufacturer details innovations in and scope of virtual patient engagement
    • Changes in usage of selected metrics for measuring success of patient advocacy activities and relationships due to the emergence of the global pandemic
    • Tools to be used in next 3 months to measure the success of patient advocacy activities

    III. Communication Frequency, Staffing, and Post-Pandemic Change

    • Frequency of reaching out to advocacy partners to provide support around access or information
    • Changes in staffing since COVID-19
    • Change in the number of advocacy groups supported since the global pandemic
    • Approach to supporting advocacy groups after the global pandemic is over